Artal Group S.A. Clovis Oncology, Inc. Call Options Transaction History

Artal Group S.A.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $2.41 Million - $3.86 Million	-500,000 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$3.77 - $11.0 $942,500 - $2.75 Million	-250,000 Reduced 33.33%	500,000 $3.18 Million
Q4 2019 Feb 13, 2020	BUY	$3.0 - $16.43 $2.25 Million - $12.3 Million	750,000 New	750,000 $7.82 Million
Q1 2019 May 10, 2019	SELL	$17.66 - $30.28 $3.53 Million - $6.06 Million	-200,000 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$11.63 - $32.67 $2.33 Million - $6.53 Million	200,000 New	200,000 $3.59 Million

Q3 2018 Nov 09, 2018	SELL	$29.37 - $49.48 $2.94 Million - $4.95 Million	-100,000 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$42.06 - $62.4 $6.31 Million - $9.36 Million	-150,000 Reduced 60.0%	100,000 $4.55 Million
Q1 2018 May 10, 2018	BUY	$50.12 - $67.72 $5.01 Million - $6.77 Million	100,000 Added 66.67%	250,000 $13.2 Million
Q4 2017 Feb 09, 2018	BUY	$57.69 - $84.58 $8.65 Million - $12.7 Million	150,000	150,000 $10.2 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.